It is hard to get excited after looking at Abbott Laboratories' (NYSE:ABT) recent performance, when its stock has declined 5.8% over the past month. However, a closer look at its sound financials ...

We recently published Jim Cramer Discusses These 10 Stocks & AI-Led Disinflation. Abbott Laboratories (NYSE:ABT) is one of ...

We came across a bullish thesis on Abbott Laboratories on r/ValueInvesting subreddit by anonymous_sheep1. In this article, we ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

The company reported strong earnings in the second quarter of 2025. It posted revenue of $11.1 billion, which showed a 7.37% ...

Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Abbott Laboratories shares slumped Thursday after the drugmaker narrowed its full-year outlook, even as it posted better-than ...

Abbott Laboratories is a mammoth healthcare business whose market cap is around $180 billion. Even at a $30,000 investment, you would need the stock to be worth more than 33 times its valuation ...

Abbott Laboratories' long-term plan is to make headway in this massive market by launching products adapted to different regions. Abbott isn't just a diabetes company, though.

Abbott Laboratories closed 6.52% below its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories increased its revenue from $20.2 billion in FY 2014 to $40.1 billion in FY 2023. That’s a compound annual growth rate of 7.9%. Very solid.